Lung adenocarcinoma is the leading cause of cancer death worldwide. Two studies led by Carla Kim, PhD, in our Stem Cell Program offer insight into its early origins. Using single-cell RNAseq and mouse alveolar organoids, her team showed that mutations in the KRAS oncogene transform alveolar progenitor cells to a more plastic state. This change, needed for lung repair, is co-opted by the cancer. Now, Kim’s team is using human airway and alveolar organoids, made from bronchoalveolar lavage samples, to see if there are similar changes before lung tumors are detectable. 👉 http://ms.spr.ly/6048YiSK6
Boston Children's Hospital
Hospitals and Health Care
Boston, MA 151,199 followers
Where the world comes for answers.
About us
Boston Children's Hospital is a 404-bed comprehensive center for pediatric health care. As one of the largest pediatric medical centers in the United States, Boston Children's offers a complete range of health care services for children from birth through 21 years of age. (Our services can begin interventions at 15 weeks gestation and in some situations we also treat adults.) We have approximately 25,000 inpatient admissions each year and our 200+ specialized clinical programs schedule 557,000 visits annually. Last year, the hospital performed more than 26,500 surgical procedures and 214,000 radiological examinations. Our team of physicians and nurses has been recognized by a number of independent organizations for overall excellence, and we're proud to share some notable examples with you here.
- Website
- http://www.childrenshospital.org
External link for Boston Children's Hospital
- Industry
- Hospitals and Health Care
- Company size
- 10,001+ employees
- Headquarters
- Boston, MA
- Type
- Nonprofit
- Founded
- 1869
- Specialties
- Research, Patient Services, Technology, Pediatrics, Hospital, and Innovation
Locations
Employees at Boston Children's Hospital
-
Andreas Ramos
Author of 22+ books in digital marketing | Adjunct Professor | Teach university-level AI-powered digital marketing at Omnes, CSTU, DMAnc |…
-
Chris Newell
Senior Director Organizational Development at Boston Children's Hospital
-
Walter Pressey
Independent Director, Forsyth Institute
-
Michael Edson
IT Manager, Virtual Care and DH Emerging Tech
Updates
-
Prime editing can make targeted DNA insertions, deletions, and the full range of base changes (C to G, T to A, and so on) without making DNA breaks. It has great potential for reversing genetic disorders — but is it ready for prime time? A team led by Daniel Bauer, director of our Gene Therapy Program, and Sébastien Levesque hypothesized that low levels of nucleotides in non-dividing blood stem cells restrict the ability to edit. They’ve now introduced some enhancements that make prime editing more efficient. 👇
Enhancing prime editing in hematopoietic stem and progenitor cells by modulating nucleotide metabolism - Nature Biotechnology
nature.com
-
Port wine stains — capillary malformations on the skin — are the most visible manifestation of Sturge-Weber syndrome. However, up to 60 percent of babies with birthmarks in high-risk locations also have brain capillary malformations and are at risk for seizures. A retrospective study led by Anna Pinto, MD, PhD, director of our Sturge-Weber clinic, found that infants pre-treated with anti-seizure drugs were less likely to have seizures. She’s now teamed up with Yangming Ou, PhD, an expert in image analysis, to see if infants’ MRI scans could help predict their seizure risk and whether they would benefit from pre-treatment. 👇
Can we prevent seizures in Sturge-Weber syndrome? - Boston Children's Answers
https://answers.childrenshospital.org
-
“Boarding” of mental health patients in the emergency department surged during the COVID-19 pandemic. As volume grew, Boston Children’s took steps to relieve the crisis and increase access to psychiatric care. This study led by Patricia Ibeziako, MD, shows these measures decreased the average boarding time from 9.1 to 4.3 days. Work is ongoing to ensure children and teens get the right mental health care at the right time. 👇
Easing mental health boarding in the emergency room - Boston Children's Answers
https://answers.childrenshospital.org
-
Congrats, Shelly! It brings us so much joy to see one of our own achieving her best life. "This is about me and my dream. I'm going to get there slowly but surely. I will get there."
After nearly 30 years of setbacks, Roxbury mother graduates college
cbsnews.com
-
Thrilled to see our very own President and CEO, Dr. Kevin Churchwell, on Becker's Hospital Review's list of Black healthcare leaders to know!
231+ Black healthcare leaders to know | 2024
beckershospitalreview.com
-
Big congratulations to Boston Children’s own Stuart Orkin, MD, for receiving The Shaw Prize in Life Science and Medicine. The 2024 prize is shared with Swee Lay Thein of the Sickle Cell Branch, National Heart, Lung, and Blood Institute. The prize recognizes their work on understanding the fetal-to-adult hemoglobin switch — and suppressing it by targeting the BCL11A gene in people with sickle cell disease and beta thalassemia. Work in Dr. Orkin’s lab laid the groundwork for the recently FDA-approved CRISPR gene therapy, Casgevy. Read all about it here: http://ms.spr.ly/6041Yb9Hc
-
Mitochondrial transfer, pioneered at Boston Children’s by James McCully, PhD, can boost growth of blood vessels and help hearts recover from ischemic events. But until recently, no one really knew how it works. A study in Nature led by Juan Melero-Martin, PhD, finds a surprising answer that’s opening up new leads for his tissue engineering work. Separately, cardiac surgeon Sitaram Emani, MD, is investigating whether transplanted mitochondria could improve the success of cardiac transplantation and help expand the pool of potential donors. 👇
How mitochondrial transfer restores heart muscle - Boston Children's Answers
https://answers.childrenshospital.org
-
Boston Children's is a certified Center of Excellence for Luxturna, an FDA-approved gene therapy treatment. Learn more about Luxturna at the link below 👇
Offering hope to children with biallelic RPE65 retinal disease: Boston Children's is a certified Center of Excellence for Luxturna, an FDA-approved gene therapy treatment. https://lnkd.in/eYXN2fu4
-
Could blood platelets shed light on sudden infant death syndrome? Researchers in Boston Children’s Department of Pathology have shown that some infants who died from SIDS had brainstem abnormalities in serotonin and related pathways. Now, a collaboration with the Center for Platelet Research Studies at Dana-Farber/Boston Children’s finds that platelets mirror these abnormalities. This suggests that platelets could stand in as a proxy for brain tissue, accelerating SIDS research and potentially aiding diagnosis. 👇
Platelet biomarkers shed light on potential risk factors for sudden infant death syndrome (SIDS) | Dana-Farber Cancer Institute